Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from EchoIQ Limited ( (AU:EIQ) ) is now available.
Echo IQ announced that its application for a Category III Current Procedural Technology (CPT) code for EchoSolv AS in the US was unsuccessful, as per the American Medical Association’s decision. Despite this setback, the company plans to explore options for reimbursement and continue engaging with the AMA, particularly regarding the development of new CPT codes for AI-based technologies under the proposed Clinically Meaningful Algorithmic Analysis (CMAA) framework. Echo IQ remains focused on expanding the use of EchoSolv AS in the US, progressing its FDA submission for EchoSolv HF, and pursuing broader licensing and partnership opportunities, which positions it to drive adoption and create long-term value for shareholders.
The most recent analyst rating on (AU:EIQ) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.
More about EchoIQ Limited
Echo IQ is an AI and medical technology company based in Sydney, Australia, specializing in AI-driven technology and proprietary software aimed at improving decision-making in cardiology.
Average Trading Volume: 1,423,001
Technical Sentiment Signal: Sell
Current Market Cap: A$132.8M
For a thorough assessment of EIQ stock, go to TipRanks’ Stock Analysis page.